首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Journal Of Clinical Oncology

Journal Of Clinical Oncology杂志,由American Society of Clinical Oncology出版,于1983年创刊,Biweekly,出版语言English,ISSN:0732-183X,E-ISSN:1527-7755。

投稿咨询
Journal Of Clinical Oncology
Journal Of Clinical Oncology
Journal Of Clinical Oncology
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
44.7
CiteScore
14.2
期刊收录
SCI、SCIE

Journal Of Clinical Oncology(中文译名:《临床肿瘤学杂志》),ISSN:0732-183X,EISSN:1527-7755,是American Society of Clinical Oncology出版的国际性学术期刊,创刊于1983年,以Biweekly形式稳定发行,2026年总发文量约308篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达44.7,2025年期刊CiteScore为14.2,2025年期刊自引率约1.6%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Journal Of Clinical Oncology长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约2月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACanada、CHINA MAINLAND、England、France、Japan、GERMANY (FED REP GER)等为核心发文国家与地区;HARVARD UNIVERSITYUNIVERSITY OF TEXAS SYSTEM、UNIVERSITY OF CALIFORNIA SYSTEM、MEMORIAL SLOAN KETTERING CANCER CENTER、DANA-FARBER CANCER INSTITUTE、UNICANCER、MAYO CLINIC等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区
是 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区
是 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 7 / 333

98

学科:ONCOLOGY SCIE Q1 7 / 333

98.05

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 6 / 328

98.3

学科:ONCOLOGY SCIE Q1 7 / 328

98.02


中国学者近期发文

1
Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trial

Author:Rusthoven, Chad G.; Serizawa, Toru; Yamamoto, Masaaki

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 12, pp. 1174-1175. DOI: 10.1200/JCO-25-01794

2
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Stud

Author:Licitra, Lisa; Tahara, Makoto; Harrington, Kevin; Olivera Hurtado de Mendoza, Mivael; Guo, Ye; Aksoy, Sercan; Fang, Meiyu; Csőszi, Tibor; Klochikhin, Mikhail; Bueno de Oliveira, Thiago; Takahashi, Shunji; Yang, Muh-Hwa; Swiecicki, Paul L.; Even, Caroline; Fayette, Jérome; Dutcus, Corina; Okpara, Chinyere E.; Shen, Juan; Benjamin, Kimberly; Gumuscu, Burak; Haddad, Robert I

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 12, pp. 1098-1107. DOI: 10.1200/JCO-25-00570

3
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Tria

Author:Zhu, Hai-Dong; Fan, Wei-Jun; Zhao, Chang; Wang, Song; Li, Yu-Liang; Jin, Zhi-Cheng; Zhang, Zhe-Wei; Guo, Jin-He; Cheng, Hong-Tao; Zhang, Qi; Lu, Jian; Zeng, Yong-Yi; Lv, Wei-Fu; Xu, Hao; Shao, Hai-Bo; Xu, Wei-Guo; Zhao, Xu-Ya; Gu, Shan-Zhi; Lin, Hai-Lan; Zheng, Wen-Heng; Piao, Long-Zhen; Song, Yu-Sheng; Zhao, Jian-Bo; Wang, Yuan-Cheng; Hou, Zhi-Guo; Sun, Ying; Guan, Ni; Huang, Ming; Yang, Wei-Zhu; Ji, Jian-Song; Teng, Gao-Jun

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 959-969. DOI: 10.1200/JCO-25-01796

4
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001

Author:Yan, Wenqiang; Du, Chenxing; Lv, Rui; Zou, Hesong; Zhang, Shuaishuai; Yu, Tengteng; Yan, Yuting; Zhang, Yanlei; Peng, Shuixiu; Wang, Tingyu; Deng, Shuhui; Huang, Wenyang; Yi, Shuhua; Zou, Dehui; Cheng, Tao; Wang, Jianxiang; Chang, Alex H.; Qiu, Lugui; An, Gang

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 992-1002. DOI: 10.1200/JCO-25-01969

5
Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyon

Author:Wermke, Martin; Gambardella, Valentina; Kuboki, Yasutoshi; Felip, Enriqueta; Sanmamed, Miguel F.; Alese, Olatunji B.; Sayehli, Cyrus M.; Arriola, Edurne; Wolf, Jürgen; Villaruz, Liza C.; Bertulis, Julia; Studeny, Matus; Bouzaggou, Mohamed; Fang, Xiaoyan; Morgensztern, Daniel

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 1062-1064. DOI: 10.1200/JCO-25-02654

6
Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Tria

Author:Mei, Wei-Jian; Wang, Xiao-Zhong; Zhang, Xuan; Sun, Yue-Ming; Yang, Chun-Kang; Lin, Jun-Zhong; Wu, Zu-Guang; Zhang, Rui; Wang, Wei; Li, Yong; Zhuang, Ye-Zhong; Lei, Jian; Wan, Xiang-Bin; Ren, Ying-Kun; Cheng, Yong; Li, Wen-Liang; Wang, Zi-Qiang; Xu, Dong-Bo; Mo, Xian-Wei; Ju, Hai-Xing; Ye, Sheng-Wei; Zhao, Jing-Lin; Zhang, Hong; Gao, Yuan-Hong; Zeng, Zhi-Fan; Xiao, Wei-Wei; Zhang, Xiao-Peng; Li, Yun-Feng; Xie, E; Feng, Yi-Fei; Tang, Jing-Hua; Wu, Xiao-Jun; Chen, Gong; Li, Li-Ren; Lu, Zhen-Hai; Wan, De-Sen; Bei, Jin-Xin; Pan, Zhi-Zhong; Yu, Jie-Hai; Ding, Pei-Rong

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 970-980. DOI: 10.1200/JCO-25-00731

7
Mifamurtide in Nonmetastatic High-Grade Osteosarcom

Author:Li, Huan-Ning

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 1060-1060. DOI: 10.1200/JCO-25-02154

8
Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trial

Author:Huang, Sai-Wei; Liang, Ye-Lin; Tao, Ya-Lan; Li, Wen-Fei; Zhou, Guan-Qun; Mao, Yan-Ping; Guo, Rui; Chen, Lei; Xu, Sha; Liu, Xu; Zhang, Ning; Liu, Fang; Shen, Liang-Fang; Zhou, Yang-Ying; Yuan, Ya-Wei; Zou, Guo-Rong; Jin, Feng; Tang, Ling-Long; Sun, Ying; Li, Ying-Qin; Ma, Jun; Liu, Na

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 1028-1039. DOI: 10.1200/JCO-25-02111

9
Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyon

Author:Chen, Yitian; Liu, Li; Ming, Yang; Chen, Ligang

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 11, pp. 1061-1062. DOI: 10.1200/JCO-25-01894

10
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Stud

Author:Zhou, Huaqiang; Zhao, Hongyun; Hou, Xue; Wang, Yongsheng; He, Zhiyong; Li, Yongsheng; Ma, Yuxiang; Zhao, Yuanyuan; Huang, Yan; Chen, Likun; Xiao, Sa; Zhu, Hai; Zhu, Yi; Fang, Wenfeng; Zhang, Li; Yang, Yunpeng

Journal: JOURNAL OF CLINICAL ONCOLOGY. 2026; Vol. 44, Issue 10, pp. 893-902. DOI: 10.1200/JCO-25-01929


在线咨询

Journal Of Clinical Oncology

国际简称:J CLIN ONCOL参考译名:临床肿瘤学杂志

年发文量:308 CiteScore:14.2 是否预警:否 Gold OA文章占比:36.39% 研究类文章占比:97.08%

杂志社联系方式:AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, USA, VA, 22314

Journal Of Clinical Oncology